PRLD
Prelude Therapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$3.39
+3.99%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$3.28
From 52W high−48.87%
Volume1.59M
Market cap$270.53M
P/E (TTM)—
P/S (TTM)12.1x
Div yield—
Key dataOct 19, 2026
Open
$3.28
From 52W high
−48.87%
Volume
1.59M
Market cap
$270.53M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
32.0
MomentumView details →
1D Return
+3.99%
YTD Return
+15.86%
SummaryUpdated Jun 1, 2026
Prelude Therapeutics Incorporated (NASDAQ:PRLD) is a clinical-stage precision oncology company founded in 2016 and headquartered in Wilmington, Delaware. The company went public in September 2020 and focuses on discovering and developing novel precision cancer medicines targeting underserved patient populations. Prelude operates in the biotechnology sector, specifically concentrating on developing targeted therapies for various cancer types through a precision medicine approach that aims to match specific treatments to patients based on their tumor's genetic characteristics.
Similar companies
Latest newsMore news →
Prelude Therapeutics Inc reported Q2 2026 revenue of $5.704 million, a net loss of $13.921 million, and diluted EPS of -$0.14, with approximately $155 million in cash and marketable securities expected to fund operations into Q2 2028.70d agoAbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.137d ago